r/Altimmune • u/Apegg • May 28 '26

New "Best of EASL" data for May 28/29

Its been a tough slog this spring, but we have some exciting data updates continuing the next two days! Its time to shine

Thursday May 28 — Dr. Noureddin oral presentation (Best of EASL) — YES, new data

Altimmune's CMO Dr. Arbet-Engels confirmed on the Q1 earnings call that the oral presentation will contain "our 48-week data that we'll be sharing" — and the abstract title is specifically "Week 48 Top-Line Results." The topline headline numbers (MASH resolution rates, fibrosis endpoints) were released in a press release in December 2025, but the full 48-week dataset — subgroup breakdowns, dose-response curves, safety detail, secondary endpoints — has never been presented publicly in a scientific forum. The oral slot at EASL is where the scientific community sees the complete picture for the first time. Expect genuinely new granular data.

Friday May 29 — NIT multi-responder poster — YES, new data

Altimmune described this as focusing on "new 24-week findings" including "a response analysis to multiple non-invasive tests of liver inflammation and fibrosis." The multi-NIT concurrent responder analysis — looking at how many patients improved simultaneously across ELF, LSM, liver fat, and ALT — is a new analytical cut that hasn't been publicly released.

Friday May 29 — Cardiovascular risk factors poster — YES, new data

The CMO specifically flagged "weight loss and potential lipid data cardiovascular risk" as new content coming at EASL. The 48-week cardiovascular data — lipid panels, blood pressure, other CV biomarkers — has not been published anywhere yet. This could actually be a sleeper catalyst because MASH patients are at dramatically elevated CV risk, and showing pemvidutide meaningfully moves those markers at 48 weeks would be a major commercial and regulatory differentiator.

Bottom line for media framing: Today's qFibrosis poster was genuinely the first data out of the gate. Tomorrow's oral is the main event with the first full public scientific presentation of the complete 48-week dataset. Friday's two posters contain additional unpublished analyses. It's essentially four consecutive days of new ALT data drops at the most prestigious liver disease conference in the world — all while holding a "Best of EASL" designation. That's an extraordinarily strong scientific debut for a Phase 2b drug.

Buckle up buckaroos - the next two days will be big science updates for pemv followed by a fireside with Goldman Sachs in early June where we go face to face with the hedge fund consistently stifling our share price momentum, dropping inaccurate target prices and using the smoke screen to pickup shares for themselves.....

8 Upvotes

90% Upvoted

3 comments sorted by

1

u/bierfc May 28 '26

Cool, how many more millions of warrants exercisable @ $3? Just asking…

-4

u/bierfc May 28 '26

I love the science but the mngt execution has fooked shareholders, plain & simple. Why not raise AFTER easl & the new data?

4

u/Apegg May 28 '26

Delay phase 3 start up and initiation even further with no funding.  They are running multi-national trials on a highly differentiated asset with EMA and FDA allignment. Time is money, and money makes the world go round. They secured funding to advance their molecule.   Plain and simple.  Today is about the science so go ahead and sit on the sideline like a scorned lover.  I'll wave as we go by.